Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cost-effectiveness Analysis of Xpert MTB/RIF Ultra for the Diagnosis of HIV-Associated Tuberculous Meningitis.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Evaluating AL-ISS within a BNP-based model for AL amyloidosis in the daratumumab era.

Blood advances·2026
Same author

Finding ferritin footprints in 5-fluorouracil-induced cardiotoxicity.

Cardio-oncology (London, England)·2026
Same author

New onset seizure etiologies and outcomes among adults with HIV in the era of broadly available antiretroviral therapies.

Seizure·2026
Same author

Invasive and medical management approaches to non-acute myocardial ischaemic syndromes.

Nature reviews. Cardiology·2026
Same author

Stabilizers, Silencers, and Disease Stage: Lessons From Recent Trials of ATTR Cardiac Amyloidosis.

Journal of the American College of Cardiology·2025

Related Experiment Video

Updated: May 17, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Very late stent thrombosis: current concepts.

Omar K Siddiqi1, David P Faxon

  • 1Division of Cardiovascular Medicine, Boston Medical Center, Brigham and Women’s Hospital, Boston, Massachusetts 02120, USA.

Current Opinion in Cardiology
|October 19, 2012
PubMed
Summary

Drug-eluting stents (DES) reduce restenosis but can cause late stent thrombosis. New research reveals mechanisms and potential solutions for very late stent thrombosis (VLST) to improve patient outcomes.

More Related Videos

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

Related Experiment Videos

Last Updated: May 17, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Biomaterials Science

Background:

  • Drug-eluting stents (DES) are crucial for preventing neointimal hyperplasia and in-stent restenosis.
  • Complications include stent thrombosis due to incomplete healing, malapposition, and delayed reendothelialization.
  • Stent restenosis significantly increases mortality, morbidity, and negatively impacts long-term prognosis.

Purpose of the Study:

  • To review the prevalence of late and very late stent thrombosis (VLST) after DES implantation.
  • To explore the underlying mechanisms contributing to VLST.
  • To discuss recent advancements in stent technology and antiplatelet therapies for VLST prevention.

Main Methods:

  • Review of large registry studies and randomized controlled trials on DES implantation.
  • Analysis of intravascular ultrasound (IVUS) and optical coherence tomography (OCT) data.
  • Synthesis of findings on healing, neoatherosclerosis, and novel therapeutic strategies.

Main Results:

  • VLST occurs persistently at approximately 0.26% per year for up to 5 years post-DES implantation.
  • Delayed healing and neoatherosclerosis are identified as key mechanisms driving VLST.
  • Novel stent scaffolds and antiplatelet agents show promise in mitigating VLST risk.

Conclusions:

  • Very late stent thrombosis remains a significant clinical challenge following DES implantation.
  • Understanding the mechanisms of VLST is critical for developing effective prevention strategies.
  • Advancements in stent design and pharmacotherapy offer hope for reducing VLST incidence.